Ipsen Enters Partnership With Marengo on Cancer Drugs
01 Août 2022 - 7:56AM
Dow Jones News
By Cecilia Butini
Ipsen said Monday that it has entered into a strategic
partnership with Marengo Therapeutics to bring two of the company's
immuno-oncology candidate drugs into the clinical testing
phase.
The French pharma company said that, as part of the agreement,
it would make an upfront payment to Marengo of $45 million, which
would go up to $1.59 billion if all milestones are met. Tiered
sales royalty payments would also be added on top, the company
said.
The agreement centers around the development of two precision
immuno-oncology candidate drugs, Ipsen said, adding that Marengo
will led preclinical development and will expense related costs
until it can submit an application for Investigational New Drug to
the US Food and Drug Administration.
"The collaboration will leverage Marengo's proprietary R&D
expertise of a novel mechanism of T cell activation with Ipsen's
global oncology footprint for clinical development and
commercialization," the company said.
Write to Cecilia Butini at cecilia.butini@wsj.com
(END) Dow Jones Newswires
August 01, 2022 01:41 ET (05:41 GMT)
Copyright (c) 2022 Dow Jones & Company, Inc.
Ipsen (EU:IPN)
Graphique Historique de l'Action
De Juin 2024 à Juil 2024
Ipsen (EU:IPN)
Graphique Historique de l'Action
De Juil 2023 à Juil 2024